

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Regional Medical Imaging, P.C.
2486 Nerredia, Suite A
Flint, MI 48532

REPORT NUMBER(S) 13-01

2. NRC/REGIONAL OFFICE

Region III
U. S. Nuclear Regulatory Commission
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

3. DOCKET NUMBER(S)

030-31367

4. LICENSE NUMBER(S)

21-26076-01

5. DATE(S) OF INSPECTION

February 14, 2013

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:



- ☒ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- ☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		2/14/13
BRANCH CHIEF	Tamara E. Bloomer		3/8/13

Docket File Information**SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION**

1. LICENSEE/LOCATION INSPECTED:

Regional Medical Imaging, P.C.
2486 Nerredia, Suite A
Flint, MI 48532

REPORT NUMBER(S) 13-01

2. NRC/REGIONAL OFFICE

Region III
U. S. Nuclear Regulatory Commission
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

3. DOCKET NUMBER(S)

030-31367

4. LICENSE NUMBER(S)

21-26076-01

5. DATE(S) OF INSPECTION

February 14, 2013

6. INSPECTION PROCEDURES USED

87131

7. INSPECTION FOCUS AREAS

03.01-03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)

02120

2. PRIORITY

3

3. LICENSEE CONTACT

R. Hicks, MD, RSO

4. TELEPHONE NUMBER

(810) 732-1919

- ☐ Main Office Inspection Next Inspection Date: 02/12/2016
- ☒ Field Office Inspection 221 W. Roberts St., Fenton, MI
- ☐ Temporary Job Site Inspection

PROGRAM SCOPE

The licensee was a Mid-Michigan radiology practice that performed medical procedures pertaining to diagnostic testing and treatment of thyroid disease and authorized to use any byproduct material for any study permitted by 10 CFR 35.100, 35.200, and 35.300 at three locations specified on the license.

At the Fenton, Michigan facility, the nuclear medicine department was staffed with one nuclear medicine technologist (NMT) that rotates with other NMTs between the licensee's facilities and one assisting cardiac stress nurse. The licensee performs an average of 5-6 cardiac studies and 2-3 other studies Tuesdays thru Thursdays each week. Iodine-123 is administered for uptake studies and averaged none to two administrations per month. Iodine-131 administrations requiring a written directive included whole body scans, hyperthyroid treatments and post-thyroidectomy therapy which averaged 3-4 cases annually. The nuclear medicine department received unit doses from a local nuclear pharmacy as ordered. All waste was either held for decay-in-storage (DIS) or returned to the nuclear pharmacy as limited quantity shipments.

Performance Observations

The licensee's available NMT demonstrated/discussed: (1) survey meter use and calibrations; (2) package check-in procedures; (3) unit dosage prep and safe use; (4) wipe test counting; (5) waste handling; (6) sealed source inventories and leak tests; (7) routine security of licensed material; (8) dose calibrator tests; (9) quarterly radiation safety program audits; (10) any contamination events (none); (11) HAZMAT refresher training; (12) written directives and 10 CFR 35.75 requirements; and (12) dosimetry: for 2011, 350mR-DDE, 1810 mR-SDE, and 2012, 250 mR-DDE and 1350 mR-SDE.

The inspector performed independent and confirmatory radiation measurements which indicated results consistent with licensee survey records and postings.